Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives
Xiaoman Suo, Yingnan Liu, Guofang Zhang, Yang Li · 2026
Read Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives by Xiaoman Suo, Yingnan Liu, Guofang Zhang, Yang Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13220576.txt.
Description
Xiaoman Suo, Yingnan Liu, Guofang Zhang, and Yang Li write a 2026 perspective on why cancer immunotherapy keeps stalling before the clinic. Marrying nanoparticles to immune therapy promises precise, safer cancer treatment, and animal studies deliver. Human translation, though, is throttled by problems that appear inside a body.
The authors organize the obstacles as a barrier-strategy framework. A protein corona coats nanoparticles in blood and rewrites their identity. Tumor barriers blunt how well the drugs act once delivered, and how the body metabolizes and excretes the particles decides long-term safety. Against each barrier they set strategies: designing from mechanism rather than trial and error, artificial intelligence assistance in optimization, delivery systems, and safety-by-design from the first sketch. Their roadmap asks the field to invest in integrated technologies, translational models, and scalable manufacturing, arguing that nanoimmunotherapy's clinical potential will not realize itself.
Catalog record
| CREATOR | Xiaoman Suo, Yingnan Liu, Guofang Zhang, Yang Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |